{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:36:55Z","timestamp":1793299015290,"version":"4.5.0"},"update-to":[{"DOI":"10.1371\/journal.pmed.1004878","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:00:00Z","timestamp":1793232000000}}],"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-065751"],"award-info":[{"award-number":["INV-065751"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32AI074492"],"award-info":[{"award-number":["T32AI074492"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Effective vaccines against\n                      <jats:italic>Shigella<\/jats:italic>\n                      , the leading bacterial cause of diarrheal disease globally, could prevent morbidity and mortality from shigellosis as well as limit antibiotic resistance. Several\n                      <jats:italic>Shigella<\/jats:italic>\n                      vaccine candidates are in late stages of development, and the design of large Phase 3 trials in target populations is underway. In high incidence settings, children are expected to rapidly accrue natural immunity such that after repeated pathogen exposure, unvaccinated infants may have similar levels of immunity as vaccinated infants. For this reason, in these settings estimates of vaccine efficacy (VE) may underestimate expected efficacy in a fully na\u00efve population. To set expectations and support optimal planning of future\n                      <jats:italic>Shigella<\/jats:italic>\n                      vaccine trials, we aimed to quantify the potential impact of this phenomenon on VE estimates under different surveillance strategies and assumptions about\n                      <jats:italic>Shigella<\/jats:italic>\n                      immunity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We simulated\n                      <jats:italic>Shigella<\/jats:italic>\n                      vaccine trials in low-, medium-, and high-burden settings under different assumptions about vaccine- and infection-conferred immunity. We estimated VE against severe,\n                      <jats:italic>Shigella<\/jats:italic>\n                      -attributable disease and any\n                      <jats:italic>Shigella<\/jats:italic>\n                      -attributable diarrhea under six trial designs: active surveillance for\n                      <jats:italic>Shigella<\/jats:italic>\n                      infection or symptom-based reporting paired with single-outcome, stratified recurrent outcome, or crude recurrent-outcome Cox proportional hazards models. In each scenario, we evaluated bias, 95% confidence interval (CI) coverage, and the false negative rate. Only the trial design using active surveillance for infection and single outcome models was consistently unbiased across all examined scenarios. The other five designs underestimated VE by up to an absolute 20%, with a single outcome model paired with symptom-based reporting performing least poorly. Bias generally was worse at higher-burden sites. For realistically sized trials, the 95% CI coverage and false negative rate were also worse at higher-burden sites. The results were sensitive to input parameters which depended on assumptions about\n                      <jats:italic>Shigella<\/jats:italic>\n                      natural history based on limited published data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The observed VE in\n                      <jats:italic>Shigella<\/jats:italic>\n                      vaccine trials is likely to underestimate true VE, though the magnitude of underestimation described here is conditional on the simulation\u2019s inputs and assumptions. Careful trial design is needed to minimize this underestimation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1004878","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:53:58Z","timestamp":1792605238000},"page":"e1004878","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the impact of naturally-acquired immunity on Shigella vaccine performance to inform clinical trials: A simulation-based modeling study"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2212-2546","authenticated-orcid":true,"given":"Avnika B.","family":"Amin","sequence":"first","affiliation":[{"name":"Rollins School of Public Health, Emory University","place":["Atlanta, Georgia, United States of America"],"department":["Department of Biostatistics and Bioinformatics"]},{"name":"Rollins School of Public Health, Emory University","place":["Atlanta, Georgia, United States of America"],"department":["Department of Epidemiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-7597","authenticated-orcid":true,"given":"Maria","family":"Garcia Quesada","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University","place":["Atlanta, Georgia, United States of America"],"department":["Department of Epidemiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9126-7030","authenticated-orcid":true,"given":"Daniel","family":"Trudell","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University","place":["Atlanta, Georgia, United States of America"],"department":["Department of Biostatistics and Bioinformatics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3884-0921","authenticated-orcid":true,"given":"Natalie E.","family":"Dean","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University","place":["Atlanta, Georgia, United States of America"],"department":["Department of Biostatistics and Bioinformatics"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-0068","authenticated-orcid":true,"given":"Benjamin A.","family":"Lopman","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University","place":["Atlanta, Georgia, United States of America"],"department":["Department of Epidemiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4956-0418","authenticated-orcid":true,"given":"James A.","family":"Platts-Mills","sequence":"additional","affiliation":[{"name":"University of Virginia","place":["Charlottesville, Virginia, United States of America"],"department":["Division of Infectious Diseases & International Health"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-3747","authenticated-orcid":true,"given":"Elizabeth T.","family":"Rogawski McQuade","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health, Emory University","place":["Atlanta, Georgia, United States of America"],"department":["Department of Epidemiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"issue":"10051","key":"pmed.1004878.ref001","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(16)31529-X","article-title":"Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study","volume":"388","author":"J Liu","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"pmed.1004878.ref002","article-title":"Use of quantitative molecular diagnostic methods to assess the aetiology, burden, and clinical characteristics of diarrhoea in children in low-resource settings: a reanalysis of the MAL-ED cohort study","volume":"6","author":"JA Platts-Mills","year":"2018","journal-title":"Lancet Glob Health"},{"key":"pmed.1004878.ref003","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"T Vos","year":"2020","journal-title":"The Lancet"},{"issue":"8","key":"pmed.1004878.ref004","first-page":"651","article-title":"Global burden of Shigella infections: implications for vaccine development and implementation of control strategies","volume":"77","author":"KL Kotloff","year":"1999","journal-title":"Bull World Health Organ"},{"key":"pmed.1004878.ref005","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab434","article-title":"Pathogens associated with linear growth faltering in children with diarrhea and impact of antibiotic treatment: the global enteric multicenter study","volume":"224","author":"D Nasrin","year":"2021","journal-title":"J Infect Dis"},{"issue":"12","key":"pmed.1004878.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(18)30351-6","article-title":"Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study","volume":"6","author":"ET Rogawski","year":"2018","journal-title":"Lancet Glob Health"},{"issue":"9608","key":"pmed.1004878.ref007","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0140-6736(07)61690-0","article-title":"Maternal and child undernutrition: global and regional exposures and health consequences","volume":"371","author":"RE Black","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"pmed.1004878.ref008","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrgastro.2012.239","article-title":"The impoverished gut\u2014a triple burden of diarrhoea, stunting and chronic disease","volume":"10","author":"RL Guerrant","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pmed.1004878.ref009","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/vaccines10091376","article-title":"The Shigella vaccines pipeline","volume":"10","author":"CA MacLennan","year":"2022","journal-title":"Vaccines"},{"issue":"7","key":"pmed.1004878.ref010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-023-00906-1","article-title":"Antimicrobial-resistant Shigella: where do we go next?","volume":"21","author":"S Baker","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"pmed.1004878.ref011","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.3390\/ijms24054649","article-title":"Toward a Shigella vaccine: opportunities and challenges to fight an antimicrobial-resistant pathogen","volume":"24","author":"MM Raso","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"pmed.1004878.ref012","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/cid\/cix369","article-title":"Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006-2016","volume":"65","author":"CL Jonesteller","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pmed.1004878.ref013","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000001232","article-title":"A systematic review of the effect of rotavirus vaccination on diarrhea outcomes among children younger than 5 years","volume":"35","author":"LM Lamberti","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"pmed.1004878.ref014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1473-3099(18)30602-9","article-title":"Interventions to improve oral vaccine performance: a systematic review and meta-analysis","volume":"19","author":"JA Church","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pmed.1004878.ref015","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/infdis\/jix668","article-title":"Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study","volume":"217","author":"ET Rogawski","year":"2018","journal-title":"J Infect Dis"},{"issue":"11","key":"pmed.1004878.ref016","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1093\/aje\/kwae467","article-title":"Accounting for local incidence when estimating rotavirus vaccine efficacy among countries: a pooled analysis of monovalent rotavirus vaccine trials","volume":"194","author":"AB Amin","year":"2025","journal-title":"Am J Epidemiol"},{"key":"pmed.1004878.ref017","article-title":"Natural history parameters for enteric pathogens to inform modeling studies of diarrhea among children in low-resource settings: results from the MAL-ED longitudinal birth cohort","author":"AB Amin","year":"2025","journal-title":"medRxiv"},{"key":"pmed.1004878.ref018","volume-title":"WHO preferred product characteristics for vaccines against Shigella","year":"2021","edition":"1"},{"issue":"5","key":"pmed.1004878.ref019","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(25)00534-0","article-title":"The incidence and antimicrobial resistance of Shigella-attributable diarrhoea in young children in low-income and middle-income countries from the multicountry Enterics for Global Health (EFGH) Shigella Surveillance Study: a prospective, facility-based hybrid surveillance study","volume":"14","author":"MT Yousafzai","year":"2026","journal-title":"Lancet Glob Health"},{"issue":"11","key":"pmed.1004878.ref020","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/sim.8086","article-title":"Using simulation studies to evaluate statistical methods","volume":"38","author":"TP Morris","year":"2019","journal-title":"Stat Med"},{"issue":"9741","key":"pmed.1004878.ref021","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"GE Armah","year":"2010","journal-title":"Lancet"},{"issue":"9741","key":"pmed.1004878.ref022","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"K Zaman","year":"2010","journal-title":"Lancet"},{"key":"pmed.1004878.ref023","author":"W Qiu","year":"2025"},{"issue":"9888","key":"pmed.1004878.ref024","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"KL Kotloff","year":"2013","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1004878","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:00:00Z","timestamp":1793232000000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:06:34Z","timestamp":1793297194000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1004878"}},"subtitle":[],"editor":[{"given":"Simon","family":"Cauchemez","sequence":"first","affiliation":[{"name":"Institut Pasteur","place":["FRANCE"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1004878","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]}}}